Brand Intelligence Graph
Company Overview
About Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.
Business Model & Competitive Advantage
Pliant's lead asset bexotegrast (PLN-74809) is a dual αvβ6/αvβ1 inhibitor advancing in Phase 2b/3 trials for IPF — a fatal lung scarring disease with median survival of 3–5 years after diagnosis. IPF affects 100,000+ U.S. patients with two approved therapies that only slow progression. Bexotegrast's Phase 2 data showed lung function stabilization and biomarker improvements that have sustained investor and partner interest.
Competitive Landscape 2025–2026
Listed on Nasdaq since 2019, Pliant has established itself as the leading pure-play integrin inhibitor company for fibrosis. The company's pipeline extends to liver fibrosis (PSC, MASH) and kidney fibrosis, targeting markets where no approved anti-fibrotic therapies exist and where integrin biology is well-validated by genetics and preclinical models.
Key Differentiators
Strong Challenger
Pliant Therapeutics is an established challenger with significant market presence and competitive offerings in BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Pliant Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Pliant Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Pliant Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Pliant Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →